Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-26 4:26 pm Purchase | 2024-06-03 | 13D | Inhibrx Biosciences, Inc. INBX | Kayyem Jon Faiz | 1,149,046 7.900% | 330,471 (+40.37%) | Filing History |
| 2025-02-26 4:16 pm Purchase | 2024-09-12 | 13D | Inhibrx Biosciences, Inc. INBX | Mark Lappe | 925,413 6.400% | 164,000 (+21.54%) | Filing History |
| 2025-02-04 3:45 pm Purchase | 2024-12-31 | 13G | Inhibrx Biosciences, Inc. INBX | BlackRock Inc. BLK | 831,807 5.700% | 831,807 (New Position) | Filing History |
| 2024-11-14 8:14 pm Purchase | 2024-05-30 | 13G | Inhibrx Biosciences, Inc. INBX | Perceptive Advisors LLC | 1,488,553 9.900% | 1,488,553 (New Position) | Filing History |
| 2024-06-07 4:23 pm Purchase | 2024-05-29 | 13G | Inhibrx Biosciences, Inc. INBX | VIKING GLOBAL INVESTORS LP | 1,787,705 12.300% | 1,787,705 (New Position) | Filing History |
| 2024-06-03 8:45 pm Purchase | 2024-05-29 | 13D | Inhibrx Biosciences, Inc. INBX | Kayyem Jon Faiz | 818,575 5.650% | 818,575 (New Position) | Filing History |
| 2024-06-03 8:43 pm Purchase | 2024-05-29 | 13D | Inhibrx Biosciences, Inc. INBX | Mark Lappe | 761,413 5.260% | 761,413 (New Position) | Filing History |
| 2024-05-31 4:30 pm Purchase | 2024-05-30 | 13G | Inhibrx Biosciences, Inc. INBX | Sanofi | 1,157,926 8.000% | 1,157,926 (New Position) | Filing History |